Heart failure is a significant global health issue. More than half of the people who develop heart failure die within 5 years. Current treatments do not help the largest group of these patients – those with heart failure with preserved ejection fraction (HFpEF) – and have limited effectiveness for HFrEF patients. HFpEF has been called the greatest unmet need in cardiovascular disease given the number of heart failure deaths per year and the proportion of patients with HFpEF.
Genuity Science’s Heart Failure Dataset is a comprehensive discovery cohort for chronic HFpEF and HFrEF. Clinicogenomic data for this cohort includes whole genome sequencing at a typical 30x depth along with other omic and deep phenotype data. The cohort is powered for discovery, and enriched for those with HFpEF or HFrEF. Longitudinal (retrospective) data are available, and a subset of participants are available for follow-up.
Uniquely, 2D-Echocardiogram data and detailed echo reports are available. For many participants, these data are available within 6 months prior to sample collection. These data enable detailed confirmation of disease subtype and progression.
Genuity Science partners with drug discovery teams in many disease areas to provide answers to their toughest research questions. Learn more about our approach below and see how deeper, richer datasets can accelerate your research program.
Watch this recent webinar to hear from Genuity scientists and colleagues about the state of genomically-guided drug development for heart failure. Speakers also cover opportunities for novel therapeutics being explored in their own research.
We start by combining population-scale high quality whole genome sequence data with detailed clinical phenotype data to help distinguish signal from noise for a given disease. Distilling candidate targets from initial hits requires several layers of analysis. These analysis phases work like a funnel to narrow down and genomically validate hits. Our experienced team of scientists works with you every step of the way with a goal of delivering candidate targets for your drug development program.
In this webinar, Genuity Science Principal Scientist Anthony Ryan, PhD discusses the importance and value of deep phenotyping when looking for genomic associations to disease.